New preclinical models for angioimmunoblastic T-cell lymphoma: filling the GAP

Mouse models are essential to study and comprehend normal and malignant hematopoiesis. The ideal preclinical model should mimic closely the human malignancy. This means that these mice should recapitulate the clinical behavior of the human diseases such as cancer and therapeutic responses with high...

Descripción completa

Detalles Bibliográficos
Autores principales: Mhaidly, Rana, Krug, Adrien, Gaulard, Philippe, Lemonnier, François, Ricci, Jean-Ehrland, Verhoeyen, Els
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427806/
https://www.ncbi.nlm.nih.gov/pubmed/32796826
http://dx.doi.org/10.1038/s41389-020-00259-x
_version_ 1783570954372251648
author Mhaidly, Rana
Krug, Adrien
Gaulard, Philippe
Lemonnier, François
Ricci, Jean-Ehrland
Verhoeyen, Els
author_facet Mhaidly, Rana
Krug, Adrien
Gaulard, Philippe
Lemonnier, François
Ricci, Jean-Ehrland
Verhoeyen, Els
author_sort Mhaidly, Rana
collection PubMed
description Mouse models are essential to study and comprehend normal and malignant hematopoiesis. The ideal preclinical model should mimic closely the human malignancy. This means that these mice should recapitulate the clinical behavior of the human diseases such as cancer and therapeutic responses with high reproducibility. In addition, the genetic mutational status, the cell phenotype, the microenvironment of the tumor and the time until tumor development occurs, should be mimicked in a preclinical model. This has been particularly challenging for human angioimmunoblastic lymphoma (AITL), one of the most prominent forms of peripheral T-cell lymphomas. A complex network of interactions between AITL tumor cells and the various cells of the tumor microenvironment has impeded the study of AITL pathogenesis in vitro. Very recently, new mouse models that recapitulate faithfully the major features of human AITL disease have been developed. Here, we provide a summary of the pathology, the transcriptional profile and genetic and immune-phenotypic features of human AITL. In addition, we give an overview of preclinical models that recapitulate more or less faithfully human AITL characteristics and pathology. These recently engineered mouse models were essential in the evaluation of novel therapeutic agents for possible treatment of AITL, a malignancy in urgent need of new treatment options.
format Online
Article
Text
id pubmed-7427806
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-74278062020-08-27 New preclinical models for angioimmunoblastic T-cell lymphoma: filling the GAP Mhaidly, Rana Krug, Adrien Gaulard, Philippe Lemonnier, François Ricci, Jean-Ehrland Verhoeyen, Els Oncogenesis Review Article Mouse models are essential to study and comprehend normal and malignant hematopoiesis. The ideal preclinical model should mimic closely the human malignancy. This means that these mice should recapitulate the clinical behavior of the human diseases such as cancer and therapeutic responses with high reproducibility. In addition, the genetic mutational status, the cell phenotype, the microenvironment of the tumor and the time until tumor development occurs, should be mimicked in a preclinical model. This has been particularly challenging for human angioimmunoblastic lymphoma (AITL), one of the most prominent forms of peripheral T-cell lymphomas. A complex network of interactions between AITL tumor cells and the various cells of the tumor microenvironment has impeded the study of AITL pathogenesis in vitro. Very recently, new mouse models that recapitulate faithfully the major features of human AITL disease have been developed. Here, we provide a summary of the pathology, the transcriptional profile and genetic and immune-phenotypic features of human AITL. In addition, we give an overview of preclinical models that recapitulate more or less faithfully human AITL characteristics and pathology. These recently engineered mouse models were essential in the evaluation of novel therapeutic agents for possible treatment of AITL, a malignancy in urgent need of new treatment options. Nature Publishing Group UK 2020-08-14 /pmc/articles/PMC7427806/ /pubmed/32796826 http://dx.doi.org/10.1038/s41389-020-00259-x Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Review Article
Mhaidly, Rana
Krug, Adrien
Gaulard, Philippe
Lemonnier, François
Ricci, Jean-Ehrland
Verhoeyen, Els
New preclinical models for angioimmunoblastic T-cell lymphoma: filling the GAP
title New preclinical models for angioimmunoblastic T-cell lymphoma: filling the GAP
title_full New preclinical models for angioimmunoblastic T-cell lymphoma: filling the GAP
title_fullStr New preclinical models for angioimmunoblastic T-cell lymphoma: filling the GAP
title_full_unstemmed New preclinical models for angioimmunoblastic T-cell lymphoma: filling the GAP
title_short New preclinical models for angioimmunoblastic T-cell lymphoma: filling the GAP
title_sort new preclinical models for angioimmunoblastic t-cell lymphoma: filling the gap
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427806/
https://www.ncbi.nlm.nih.gov/pubmed/32796826
http://dx.doi.org/10.1038/s41389-020-00259-x
work_keys_str_mv AT mhaidlyrana newpreclinicalmodelsforangioimmunoblastictcelllymphomafillingthegap
AT krugadrien newpreclinicalmodelsforangioimmunoblastictcelllymphomafillingthegap
AT gaulardphilippe newpreclinicalmodelsforangioimmunoblastictcelllymphomafillingthegap
AT lemonnierfrancois newpreclinicalmodelsforangioimmunoblastictcelllymphomafillingthegap
AT riccijeanehrland newpreclinicalmodelsforangioimmunoblastictcelllymphomafillingthegap
AT verhoeyenels newpreclinicalmodelsforangioimmunoblastictcelllymphomafillingthegap